MAY 29, 2014 12:00 PM PDT

Navigating the Complexities of the Human Oncoproteome with the SigNET KnowledgeBank

C.E. CREDITS: CE
Speakers
  • Professor, Department of Medicine, University of British Columbia, President & Chief Scientific Officer, Kinexus Bioinformatics Corporation
    Biography
      Dr. Steven Pelech has been the founder, president and chief scientific officer of Kinexus Bioinformatics Corporation for 15 years. He was previously the founder and president of Kinetek Pharmaceuticals, Inc. for 6 years. Prior to this, he spent 5 years in post-doctoral training with Sir Philip Cohen at the University of Dundee and Nobel laureate Dr. Edwin Krebs at the University of Washington in Seattle. Dr. Pelech was a founding scientist of the Biomedical Research Centre and of the Brain Research Centre located at the University of British Columbia (UBC). Since 1988, he has concurrently been on faculty at UBC and is presently a full professor in the Department of Medicine in the Division of Neurology. Dr. Pelech received his B.Sc. (1979; Honours) and Ph.D. (1982) degrees in Biochemistry from UBC. He has authored over 220 scientific peer- reviewed publications about signal transduction and is one of the discoverers of the MAP kinases. His recent focus has been on the development of a suite of open-access, on-line KiNET databases and SigNET knowledgebases, and on the creation of high content array platforms with antibodies and peptides to support systems proteomics research. He has served on grant review panels and as an ad-hoc reviewer for over 30 granting agencies and as an external reviewer for over 30 scientific journals.

    Abstract:

    The human genome encodes ~21,500 proteins that are subject to reversible phosphorylation at nearly 1 million phosphosites by about 538 protein kinases and 156 protein phosphatases. Amongst other regulatory proteins, these classes of proteins play a central role in cancer as oncoproteins (OP), tumour-requiring proteins (TRP) or tumour suppressor proteins (TSP). They can be distinguished in part by their mutation patterns across thousands of tumour specimens. OP feature highly restricted mutations that produce a gain of function, commonly by loss of repression by inhibitory domains or mimicry of activating phosphorylation sites with acid amino acid residue substitutions. TSP typically feature an extensive range of mutation types and locations in their genes, which lead to their loss of function. By contrast, TRP display extremely low rates of mutation in human cancers, about 5 to 10-fold lower that the background mutation rates evident in bystander genes. TRP may serve as ideal targets for cancer drug development as they may be more commonly required for cancer development than OP, and they may be less tolerant to mutations that facilitate drug resistance. Interestingly, many OP are down-regulated and TSP are up-regulated in their protein levels in human tumours, which indicates that intracellular regulatory networks typically evoke compensatory mechanisms to restore growth control or induce apoptosis. Therefore, gene expression and mutation data has to be interpreted in the context of integrated signalling pathways. The open-access, on-line suite of SigNET KnowledgeBases offered by Kinexus provide extensive known and predictive information of human proteins, their gene expression, interactions and phosphorylation, and in the case of protein kinases, drug interactions. The new OncoNET website (www.onconet.ca) is a repository of detailed information about the mRNA expression and mutation patterns for nearly 3000 genes linked to diverse types of human cancers.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...